Efficacy and Safety of Continuing Bevacizumab beyond Disease Progression plus Docetaxel in Patients with Non-Small Cell Lung Cancer: A Retrospective AnalysisReport as inadecuate




Efficacy and Safety of Continuing Bevacizumab beyond Disease Progression plus Docetaxel in Patients with Non-Small Cell Lung Cancer: A Retrospective Analysis - Download this document for free, or read online. Document in PDF available to download.

Background: Bevacizumab-based chemotherapy hasbeen shown to extend progression-free survival PFS of lung cancer, but itseffect on overall survival OS remains unclear. However, bevacizumab beyonddisease progression BBP significantly improved OS in patients with metastaticcolorectal cancer. Methods: Therefore, we retrospectively analysed 22 patientswith non-small cell lung cancer NSCLC who were treated with docetaxel plusBBP at the Department of Thoracic Oncology, Kansai Medical University HirakataHospital, between November 2009 and March 2013. Results: The response rate was31.8% and the disease control rate was 86.4%. The median PFS was 4.5 months95% confidence interval CI, 2.5 - 8.7 months and the median OS was 17.2months 95% CI, 8.5 - 25.9 months. Grade 3 and 4 adverse events includedleukocytopenia 68.2%, neutropenia 77.3%, fatigue 9.1%, proteinuria9.1%, febrile neutropenia 4.5%, anemia 4.5%, and anorexia 4.5%.Conclusion: Docetaxel plus BBP was found to be generally well tolerated andeffective.

KEYWORDS

Bevacizumab beyond Disease Progression, NSCLC, Second-Line Chemotherapy, Docetaxel

Cite this paper

Yokoi, T. , Kurata, T. , Torii, Y. , Katashiba, Y. , Ogata, M. , Satsutani, N. , Niki, M. , Katashiba, N. , Kibata, K. and Nomura, S. 2015 Efficacy and Safety of Continuing Bevacizumab beyond Disease Progression plus Docetaxel in Patients with Non-Small Cell Lung Cancer: A Retrospective Analysis. Advances in Lung Cancer, 4, 8-15. doi: 10.4236-alc.2015.41002.





Author: Takashi Yokoi1,2*, Takayasu Kurata1,2, Yoshitaro Torii1,2, Yuichi Katashiba1,2, Makoto Ogata1, Naoko Murakami Satsutani1,2, Maiko

Source: http://www.scirp.org/



DOWNLOAD PDF




Related documents